We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
(-25%)
Cap. Flow
-$347M
Cap. Flow
% of AUM
-19.1%
Top 10 Holdings %
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$9.22M |
| 2 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$7.3M |
| 3 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$7.22M |
| 4 |
United Therapeutics
UTHR
|
+$5.06M |
| 5 |
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
|
+$4.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$22.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$18.2M |
| 3 |
Viatris
VTRS
|
+$18.1M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$15M |
| 5 |
Edwards Lifesciences
EW
|
+$11.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 10.47% |
| 2 | Technology | 0.45% |
| 3 | Consumer Staples | 0.1% |
| 4 | Industrials | 0.09% |
| 5 | Materials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Eli Lilly
LLY
$1.09T
| $200M | 11.03% |
23,794
+1,939
| +9% | +$161K |
|
2
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $197M | 10.83% |
17,499
-8,001
| -31% | -$734K |
|
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $184M | 10.09% |
9,000
-7,250
| -45% | -$1.49M |
|
|
4
CALL
Biogen
BIIB
$30.4B
| $105M | 5.79% |
3,437
+347
| +11% | +$99.7K |
|
5
CALL
Gilead Sciences
GILD
$167B
| $98.7M | 5.43% |
9,754
-142
| -1% | -$14.8K |
|
6
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $41.2M | 2.27% |
5,880
+2,736
| +87% | +$148K |
|
|
7
PUT
Biogen
BIIB
$30.4B
| $38M | 2.09% |
1,240
-179
| -13% | -$51.4K |
|
8
CALL
AbbVie
ABBV
$465B
| $34M | 1.87% |
5,739
-1,717
| -23% | -$98.9K |
|
9
iShares Russell 2000 ETF
IWM
$80.4B
| $33.1M | 1.82% |
294,400
-32,768
| -10% | -$3.78M |
|
|
10
PUT
Alkermes
ALKS
$8.47B
| $25.1M | 1.38% |
+3,156
| New | +$221K |
|
|
MDCO
11
CALL
DELISTED
Medicines Co
MDCO
| $23.7M | 1.3% |
6,348
-5,401
| -46% | -$204K |
|
|
12
PUT
Eli Lilly
LLY
$1.09T
| $23.6M | 1.3% |
2,804
+366
| +15% | +$30.4K |
|
|
ZGNX
13
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $22.4M | 1.23% |
15,182
-15,933
| -51% | -$214K |
|
|
GWPH
14
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $22.1M | 1.22% |
3,183
+471
| +17% | +$38.4K |
|
|
ALXN
15
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $18.6M | 1.02% |
975
| – | – |
|
16
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
| $14.9M | 0.82% |
4,175
+1,916
| +85% | +$67.5K |
|
|
17
PUT
Viatris
VTRS
$20.8B
| $14.8M | 0.81% |
2,732
-3,024
| -53% | -$145K |
|
|
18
PUT
AbbVie
ABBV
$465B
| $14.5M | 0.8% |
2,452
+180
| +8% | +$10.4K |
|
|
19
CALL
BioMarin Pharmaceuticals
BMRN
$12B
| $13.7M | 0.75% |
1,308
-1,067
| -45% | -$111K |
|
|
ANAC
20
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $13.4M | 0.74% |
1,188
+1,088
| +1,088% | +$120K |
|
|
21
CALL
Viatris
VTRS
$20.8B
| $13.3M | 0.73% |
2,452
+705
| +40% | +$33.9K |
|
22
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $12.7M | 0.7% |
3,302
+1,466
| +80% | +$47.5K |
|
|
23
PUT
United Therapeutics
UTHR
$26.1B
| $12.5M | 0.69% |
+800
| New | +$116K |
|
24
PUT
Apple
AAPL
$4.99T
| $12.5M | 0.69% |
+4,736
| New | +$135K |
|
|
25
CALL
United Therapeutics
UTHR
$26.1B
| $12.2M | 0.67% |
778
-140
| -15% | -$20.4K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q4 2015 Portfolio in Review
As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.
- Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
- Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
- Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
- Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
- Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
- Sabby Management opened 56 new positions and closed 122 in Q4 2015.
- Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.
Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.